Subject Index

Italic page numbers indicate figures; page number followed by “t” indicate tables.

A

Acoustic neuroma, 35–36, 47–58
  bilateral, 47
  cystic, 47, 58
  genetic factors and, 47
  growth patterns of, 47
  hearing loss due to, 47, 49, 50
  management algorithm for, 50
  management options for, 47
  in neurofibromatosis 3, 47, 55, 57
  observation with serial imaging of, 47
  radiosurgery for, 49–58
    clinical results of gamma knife radiosurgery, 52–54, 52–55
    clinical results of LINAC radiosurgery, 55
    clinical results of proton beam radiosurgery, 55
    clinical results of stereotactic radiation therapy, 55–56
    compared with microsurgery, 56–57
    dose delivery for, 52
    dose planning for, 51, 51
    dose prescription for, 51–52
    facial nerve and trigeminal nerve function after, 55
    after failed microsurgery, 57
    follow-up evaluations after, 52
    gamma knife radiosurgery, 35–36, 49
    goals of, 49
    hearing preservation after, 53–54, 53–54
    microsurgery after, 57–58
    myths about, 57–58
    in neurofibromatosis, 3, 55, 57
    outcomes of, 48t, 49t
    patient evaluation for, 49–50
    postoperative care after, 52
    radiation-induced cancers and, 58
    technique for, 50–51
    tumor growth control after, 52–53, 52–53
  surgical removal of, 47–49
    compared with radiosurgery, 56–57
    complications of, 48
    eye-related problems after, 49
    facial function after, 35, 36, 47–48
    hearing outcome after, 3, 35, 48
    patients’ perspective on outcome of, 48–49
    after radiosurgery, 57–58
    recurrence/residual tumor after, 48
    surgical approaches for, 47
    tinnitus after, 48

Adrenocorticotropic hormone excess. See Cushing’s disease

Allograft, to enhance spinal fusion, 63–64

Alternative Dispute Resolution, 122

American Association of Neurological Surgeons (AANS), 10, 145

5-Aminolevulinic acid (ALA), in resection of gliomas, 20–26, 21
  dexamethasone pretreatment for, 21
  dosage of, 21
  equipment for, 22–23, 23

extent of resection, 24
  implementation during surgery, 23, 23
  intraoperative photosensitization of brain tissue by, 22
  light protection for, 21–22
  pharmacokinetics of, 21
  photobleaching and, 23–24
  pitfalls in, 24, 24–25, 25
  safety and efficacy of, 20, 21
  timing of administration of, 21

Amundsen, Roald, 10, 11, 12

Anterior approach for cervical ossification of posterior longitudinal ligament (OPLL), 127–129, 128–129, 130

Apparent diffusion coefficient (ADC) maps, for tumor resection, 15, 15

Arteriovenous malformations (AVMs)
  management options for, 108, 109
  radiosurgery for, 108–117
    dosage for, 110, 110
    dural AVMs, 116
    early adverse effects of, 112
    embolization before, 108, 110, 116–117
    future directions for, 117
    imaging changes after, 112–113, 113
    initial experience with, 108–109
    late complications of, 114
    management of large AVMs, 115
    management of residual AVM after, 114–115, 115
    permanent sequelae of, 113, 114t
    Pittsburgh experience with, 109–111, 109t
    probability of AVM obliteration with, 112
    risk of hemorrhage after, 111–112, 112t
    staged volume radiosurgery, 110–111, 115–116
    technical considerations for, 109–111, 110t
    risk of hemorrhage from, 108, 111

Astrocytoma
  anaplastic, 20
  Daumas-Duport classification of, 39, 39
  fibrillary, 38, 39
  gamma knife radiosurgery for, 37t, 38–39
  grade II, 39, 39
  juvenile pilocytic, 38, 38

B

Backlund, Erik-Olof, 76, 85

Ballard, Robert, 3, 3

BCNU-impregnated polymer implantation, 27–29, 28, 29

Bioactive strategies to enhance spinal fusion, 65–66, 65t
  bone marrow aspirate and blood spin-down technologies, 64, 66
  bone morphogenetic proteins, 65–66
  composite technologies, 66
  cytokines and other inductive agents, 66
  gene therapy, 66

Biosensing strategies to enhance spinal fusion, 68–69, 70
  complexity of bone loading, 68–69, 71
optimizing bone loading and bone-loading rates, 69
Bladder function in spinal cord injury, improved by CB2 agonist
therapy (mouse). 173, 174, 175, 176
Blood spin-down technologies, to enhance spinal fusion, 64, 66
Bone graft substitutes, to enhance spinal fusion, 63–65
allograft, 63–64
components of bone healing, 64
demineralized bone matrix, 65
xenograft, 65
Bone healing
components of, 64
phases of, 63, 64
Bone marrow aspirate (BMA), to enhance spinal fusion, 64, 66
Bone morphogenetic proteins (BMPs), to enhance spinal fusion,
65–66
Brain abscess, image-guided management of, 81
Brain cysts
delayed formation after radiosurgery for AVMs, 114
stereotactic aspiration of, 80, 80t
Brain hemorrhage
after radiosurgery for cavernous malformations, 97–99
risk from AVMs, 108, 111
after radiosurgery, 111–112, 112t
after stereotactic procedures, 79–80, 80t
Brain metastases, radiosurgery for, 37t, 40–42, 41
metastases from melanoma and renal cell carcinoma, 150–158
clinical management strategy for, 150–151
data collection for analysis of, 150
local control rate for, 154–156, 154t, 155–156, 157
patient population for, 151, 152t
planning and implementation of, 151
response and survival after, 151–154, 152–153, 153t, 157
statistical analysis of, 151
whole-brain radiotherapy and, 156, 156, 157–158
Perfexion gamma knife, 44
Brain tumor resection, 12–18
detection of neural network activity for, 18, 18
emerging neuroimaging technologies for, 15–17
apparent diffusion coefficient maps, 15, 15
diffusion tensor imaging, 17, 17, 20, 160–163, 161–162
functional magnetic resonance imaging, 16
magnetic resonance perfusion and cerebral blood volume,
16, 16–17
magnetoencephalography, 17
quantitative T2 imaging, 15–16, 16
fluorescence-guided resection of gliomas using ALA, 20–26, 21
intraoperative stimulation mapping for, 17, 18
physiological imaging: magnetic resonance spectroscopy for,
12–15, 15
Brain tumors. See also specific tumors
drug delivery techniques for, 27–33
convection-enhanced delivery, 29–33, 30, 31
drug-impregnated polymer implantation, 27–29, 28, 29
herpes simplex virus-mediated boost radiosurgery for, 40, 40
innovation in glioma management, 37–40
grade II astrocytoma/oligodendroglioma, 39, 39, 39t
juvenile pilocytic astrocytoma, 38, 38
malignant gliomas, 39–40
innovation in skull base tumor management, 35–37, 36, 36t–38t
metastatic (See Brain metastases)
role of neurosurgeon in management of, 35–44
Brainstem cavernous malformations, 88–94
case examples of, 91–93, 91–93
epidemiology of, 88
evaluation of, 89
genesis associated with, 88, 89t
intrinsic vs. exophytic, 94
management of, 90, 90t
operative technique for, 93
pathogenesis of, 88–89
in pregnancy, 91, 93
presentation of, 89
prognosis for, 10
radiosurgery for, 90, 90t
surgical approaches to, 93–94, 94t
BrainSuite, 160, 161
Brown, Russ, 76
Cannabinoid receptors, 172–176
CB2 receptor activation in murine spinal cord injury, 172–176
bladder function improved by, 173, 174, 175, 176
CB2 agonist (O-1966) properties and injection, 173
locomotive function improved by, 173–174, 174
TNF-α expression decreased by, 172, 174–175, 175
upregulation of, 173, 174
effects of CB1 receptor activation, 175–176
psychoactive effects of, 172, 176
sites of expression of, 172, 175–176
Carmustine-impregnated polymer implantation, 27–29, 28, 29
Cavernous malformations
of brainstem, 88–94
case examples of, 91–93, 91–93
epidemiology of, 88
evaluation of, 89
genesis associated with, 88, 89t
intrinsic vs. exophytic, 94
management of, 90, 90t
operative technique for, 93
pathogenesis of, 88–89
in pregnancy, 91, 93
presentation of, 89
prognosis for, 10
radiosurgery for, 90, 90t
surgical approaches to, 93–94, 94t
radiosurgery for, 90, 90t, 97–99, 98
hemorrhage protection and, 98–99
rationale for, 97–98
results of, 98
seizure protection and, 99, 104, 106
seizures secondary to, 101–107
arguments for early surgery in, 102
case examples of, 104–105, 104–105
lesionectomy for, 102, 103t, 104, 105–106

© 2008 The Congress of Neurological Surgeons

181
lesionectomy plus electrocorticography-guided resection for, 102–103
mechanisms of, 106–107
medical intractability of, 101–102
in patients with multiple cavernous malformations, 106
postsurgical anti-epileptic drug treatment for, 106
questions about management of, 101, 106
radiosurgery for, 99, 104, 106
safety of surgery for, 106
subdural electrode monitoring to define epileptogenic zone in, 103–104, 106
treatment options for, 102–104
treatment recommendations for, 105,
Cerebrospinal fluid leak, after acoustic neuroma removal, 48
Chemotherapy
for juvenile pilocytic astrocytoma, 38
for malignant gliomas, 20, 27–33
MSH6 inactivation and emergent temozolomide resistance in glioblastomas, 165–169, 166–169
surgically mediated delivery of, 27–33, 28–31
convection-enhanced delivery, 29–33, 30, 31
drug-impregnated polymer implantation, 27–29, 28, 29
Collateral-source payments, 122
Computed tomography (CT)
of cervical ossification of posterior longitudinal ligament, 126
intraoperative, 76–77, 77
for brain abscess, 81
for craniotomy, 80
development of dedicated stereotactic operating room, 76, 84, 84
for endoscopic-assisted surgery, 82, 82
for frame-based stereotactic surgery, 77–79, 77–79
for frameless stereotactic surgery, 83
for functional neurosurgery, 81–82
Congress of Neurological Surgeons, 10
Contingency fee, 122
Convection-enhanced drug delivery (CED), 29–33
clinical trials of chemotherapeutic compounds, 30
clinical trials of recombinant cytokine proteins, 30–32
future applications of, 32–33
pharmacokinetics and properties of, 29–30, 30
of radiolabeled chimeric monoclonal antibodies, 32
surrogate imaging tracers in tracking of, 30
technique for, 29
Cook, Frederick, 11, 11
Cortical brain stimulation, 2, 3
Council of Medical Specialty Societies, 145
Council of State Neurosurgical Societies, 145
Craniopharyngioma, stereotactic aspiration of, 80, 80
Craniotomy, image-guided, 76, 80–81
Cushing, Harvey, 4, 5
Cushing’s disease, 141–143
fractionated radiation therapy for, 141
initial transsphenoidal surgery for, 141, 143
results of, 142, 142
management options for recurrent or refractory disease, 141
radiosurgery for, 141, 142–143, 143
repeat transsphenoidal surgery for, 141, 142, 143
Cytokines
to enhance spinal fusion, 66
TNF-α expression decreased by CB2 agonist in spinal cord injury, 172, 174–175, 175
Cytotoxic proteins, convection-enhanced delivery of, 30–31
Dandy, Walter, 88
Daumas-Duport classification of astrocytomas, 39, 39
Degenerative spondylolisthesis, SPORT study of, 72, 75
Demineralized bone matrix (DBM), to enhance spinal fusion, 65
Dexamethasone, pretreatment for ALA administration, 21
Diffusion tensor imaging (DTI), for tumor resection, 17, 17, 20, 160–163, 161–162
Direct current stimulation, to enhance spinal fusion, 67
Drug delivery techniques, 27–33
convection-enhanced delivery, 29–33, 30, 31
drug-impregnated polymer implantation, 27–29, 28, 29
Drug-impregnated polymer implantation, 27–29, 28, 29
future applications of, 28–29
pharmacokinetics and properties of, 27–28, 29
studies for recurrent malignant gliomas, 28
studies with newly diagnosed malignant gliomas, 28
studies with newly diagnosed malignant gliomas, 28
studies with newly diagnosed malignant gliomas, 28
technique for, 27, 28
Electrophysiological strategies to enhance spinal fusion, 66–67, 67
Embolization before radiosurgery for AVMs, 108, 110, 116–117
Endoscopic-assisted surgery, image-guided, 82, 82, 83
Ethical issues in psychosurgery, 138–139
Expert witness requirements, 122
Exploration, neurosurgery as, 2–8, 2–12, 10–12
Facial nerve function, after acoustic neuroma surgery, 35, 36, 47–48, 55
Franklin, John, 6–8, 8, 11
Freeman, Walter, 138–139
Functional neurosurgery, 76, 81–82, 81t
Gamma knife radiosurgery. See Radiosurgery
Ganglioglioma, gamma knife radiosurgery for, 39
Gene therapy, to enhance spinal fusion, 66
Geographical neurosurgical workforce analysis
AANS data sets for, 145–146
data analysis, 146
in future, 148
general trends, 146, 146
methodology of, 145
professional liability insurance environment and, 145, 146, 147–148
rank order analysis, 146–147, 147, 147t
U.S. census data sets for, 146
Gliadel wafer, 27–29, 28, 29
Glioblastoma multiforme (GBM)
BCNU wafer implantation for, 28
survival time in, 9, 9, 20
Glioblastomas
MSH6 inactivation and emergent temozolomide resistance in, 165–169, 166–169
case example of, 165–166, 166
clinical study results of, 167–169
evidence of hypermutator phenotype, 166, 166–167
prediction of, 167
standard of care for, 165, 166
Gliomas
malignant
chemotherapy for, 20
fluorescence-guided resection using ALA, 20–26, 21 (See also 5-Aminolevulinic acid)
gamma knife radiosurgery for, 37t, 39–40
surgically mediated drug delivery techniques for, 27–33
radiation therapy for, 20, 27, 38
role of neurosurgeon in management of, 37–40
Global neurosurgery, 4, 4
Glorioso, Joseph, 40

H
Hall, Charles Francis, 6, 7
Hayes, Isaac, 5, 6
Health courts, 124
Hearing loss due to acoustic neuroma, 47, 49, 50
after radiosurgery, 53–54, 53–54
after surgery, 3, 35, 48
Hemorrhage
after radiosurgery for cavernous malformations, 97–99
risk from AVMs, 108, 111
after radiosurgery, 111–112, 112t
after stereotactic procedures, 79–80, 80t
Herniated lumbar disc, SPORT study of, 72–74, 73, 74t
Herpes simplex virus-mediated boost radiosurgery, 40, 40
History of neurosurgery, 4, 4
Hypercortisolemia. See Cushing’s disease
Hypothalamotomy, radiosurgical ventrolateral, in obesity, 42–43, 42–43

I
Inflammatory response in spinal cord injury, attenuation by CB2 agonist therapy (mouse), 172, 174–175, 175
Interbody spacers, to enhance spinal fusion, 65, 65
Interleukin-4 bound to Pseudomonas toxin (cpIL4-PE),
convection-enhanced delivery of, 31
Interleukin-13 bound to Pseudomonas toxin (IL13-PE),
convection-enhanced delivery of, 30, 30–31
Intraoperative imaging, 76–85
for abscess management, 81
for brain cyst aspiration, 80, 80, 80t
for brain tumor resection, 12–18

apparent diffusion coefficient maps, 15, 15
BrainSuite, 160, 161
diffusion tensor imaging, 17, 17, 20, 160–163, 161–162
fluorescence-guided resection of gliomas using ALA, 20–26, 21
functional magnetic resonance imaging, 16
intraoperative stimulation mapping, 17, 18
magnetic resonance perfusion and cerebral blood volume, 16, 16–17
magnetoencephalography, 17
physiological imaging: magnetic resonance spectroscopy, 12–15, 15
quantitative T2 imaging, 15–16, 16
for cavernous malformations of brainstem, 93
for craniotomy, 76, 80–81
development of dedicated stereotactic operating room, 76, 77, 84, 84–85
for endoscopic-assisted surgery, 82, 82, 83
for functional neurosurgery, 76, 81–82, 81t
history of, 76, 77
magnetoencephalography, 17
MRI for tumor surgery, 15–17, 15–17, 160–163
for stereotactic surgery, 76
frame-based, 77–79, 77–80, 77t
frameless, 82–83
with SurgiScope, 83, 83–84
Intraoperative stimulation mapping, for tumor resection, 17, 18

J
Jannetta, Peter, 35
Joint-and-several liability, 122
Juvenile pilocytic astrocytoma (JPA), 38, 38

K
Kane, Elisha Kent, 8, 8
Kjellberg, Raymond, 108

L
Laminoplasty, for cervical ossification of posterior longitudinal ligament, 129, 129–130
Language of professional publications, 8–9, 10
Leksell, Lars, 35, 49, 76, 77, 85, 108
Light exposure, after ALA administration, 21–22
LINAC radiosurgery for acoustic neuroma, 50–51
clinical results of, 55
stereotactic radiation therapy, 55–56
Lobotomy, 138–139
Locomotive function in spinal cord injury, improved by CB2 agonist therapy (mouse), 173–174, 174
Lumbar disc herniation, SPORT study of, 72–74, 73, 74t

M
Magnetic resonance imaging (MRI)
of cavernous malformations, 97, 98
of brainstem, 89, 91–92, 91–93
of cervical ossification of posterior longitudinal ligament, 126
of convection-enhanced drug delivery, 31
for craniotomy, 81
for cyst aspiration, 80
development of dedicated stereotactic operating room, 84–85
for frame-based stereotactic surgery, 77, 77–78
for frameless stereotactic surgery, 83
for functional neurosurgery, 81–82
of glioblastoma, 166
of juvenile pilocytic astrocytoma, 38
of petroclival meningioma, 36
for placement of cortical stimulation electrode, 3
for radiosurgery of acoustic neuroma, 50
follow-up evaluations, 52
tumor growth control, 53, 54
for radiosurgery of arteriovenous malformations, 110
postradiosurgery imaging changes, 112, 113, 115
for tumor resection, 20, 160–163
apparent diffusion coefficient maps, 15, 15
BrainSuite, 160, 161
diffusion tensor imaging, 17, 17, 20, 160–163, 161–162
functional MRI, 16
magnetic resonance perfusion and cerebral blood volume, 16, 16–17
quantitative T2 imaging, 15–16, 16
of ventrolateral hypothalamotomy in obese monkey, 42
Magnetic resonance spectroscopy (MRS), for tumor resection, 12–15, 15
Magnetencephalography (MEG), for tumor resection, 17
Maine Lumbar Spine Study (MLSS), 72
Medical malpractice. See Tort system
Melanoma, radiosurgery for brain metastases from, 150–158
Meningioma, petroclival, 36, 36
Monoclonal antibodies, radiolabeled chimeric, convection-enhanced delivery of, 32
MSH6 inactivation and emergent temozolomide resistance in glioblastomas, 165–169, 166–169
case example of, 165–166, 166
clinical study results of, 167–169
evidence of hypermutator phenotype, 166, 166–167
prediction of, 167
Myelopathy, due to cervical ossification of posterior longitudinal ligament, 126

O

Obesity, radiosurgical ventrolateral hypothalamotomy in, 42–43
Oligodendroglioma, 38, 39
Oncopolitics, 35–44
Ossification of posterior longitudinal ligament (OPLL), cervical, 126–131
anterior approach to, 127–129, 128–129, 130
conservative treatment of, 126–127
diagnosis of, 126, 127
discussion of surgical management of, 130
implants, 130
intraoperative complications, 130, 131
problems in adjacent segments, 130
etiology of, 126
laminoplasty for, 129, 129–130
neurological deficits due to, 126
surgical indication for, 127
types of, 126, 127

P

Paclitaxel, convection-enhanced delivery of, 30
Parkinson’s disease, stem cell transplants in, 133, 134, 135
Patient indemnity insurance, 124
Peary, Robert, 4, 5, 11, 11, 12
Perfexion gamma knife, 43–44, 43–44
Perry, John, 76
Physical/mechanical strategies to enhance spinal fusion, 67–68, 68, 69
Polar exploration, neurosurgery and, 2–8, 2–12, 10–12
Polyanhydride polymers impregnated with drugs, for malignant gliomas, 27–29, 28, 29
Presidential Address, 1–12
Professional liability insurance (PLI)
cost of, 145
physician supply and, 145, 146, 147–148
tort reform and, 122–123
Proton beam radiosurgery for acoustic neuroma, 50
clinical results of, 55
Psychosurgery, 138–139
Pulsed electromagnetic fields, to enhance spinal fusion, 67
Punitive damage caps, 122

R

Radiation oncologists, 36–37
Radiation therapy
for Cushing’s disease, 141
for gliomas, 20, 27, 38
grade II astrocytoma, 39
for skull base tumors, 37, 37t
stereotactic, for acoustic neuroma, 55–56
whole-brain, for brain metastases from melanoma and renal cell
carcinoma, 150, 156, 156, 157–158
Radiolabeled chimeric monoclonal antibodies, convection-
enhanced delivery of, 32

Radiosurgery
for arteriovenous malformations, 108–117
dosage for, 110, 110t
dural AVMs, 116
early adverse effects of, 112
embolization before, 116–117
future directions for, 117
imaging changes after, 112–113, 113
initial experience with, 108–109
late complications of, 114
management of large AVMs, 115
management of residual AVM after, 114–115, 115
permanent sequelae of, 113, 114t
Pittsburgh experience with, 109–111, 109t
probability of AVM obliteration with, 112
risk of hemorrhage after, 111–112, 112t
staged volume radiosurgery, 115–116
technical considerations for, 109–111, 110t

for brain metastases, 37t, 40–42, 41, 44
for brain metastases from melanoma and renal cell carcinoma,
150–158
clinical management strategy for, 150–151
data collection for analysis of, 150
local control rate for, 154–156, 154t, 155–156, 157
patient population for, 151, 152t
planning and implementation of, 151
response and survival after, 151–154, 152–153, 153t, 157
statistical analysis of, 151
whole-brain radiotherapy and, 156, 156, 157–158

cancerous malformations, 97–99, 98
of brainstem, 90, 90t
hemorrhage protection and, 98–99
rationale for, 97–98
results of, 98
seizure protection and, 99, 104, 106

for Cushing’s disease, 141, 142–143, 143

for gliomas, 38

ganglioglioma, 39
grade II astrocytoma/oligodendroglioma, 39
juvenile pilocytic astrocytoma, 38, 38
malignant gliomas, 37t, 39–40
herpes simplex virus-mediated boost, 40, 40
history and development of, 35, 76
indications for, 36t–38t, 85t
with Perfexion gamma knife, 43–44, 43–44
for skull base tumors, 36–37
acoustic neuroma, 35–36, 49, 50–55, 51–54
petroclival meningioma, 36, 36
ventrolateral hypothalamotomy in obesity, 42–43, 42–43

Renal cell carcinoma, radiosurgery for brain metastases from,
150–158

Richardson, John, 7–8
Rosenbaum, Arthur, 76
Ross, John, 6, 7

Sciatica Frequency Index, 72
Scoresby, William, 8, 8
Seizures secondary to cavernous malformations, 101–107
arguments for early surgery in, 102
case examples of, 104–105, 104–105
lesionectomy for, 102, 103t, 104
limitations of, 105–106
lesionectomy plus electrocorticography-guided resection for,
102–103
mechanisms of, 106–107
medical intractability of, 101–102
postsurgical anti-epileptic drug treatment for, 106
questions about management of, 101, 106
radiosurgery for, 99, 104, 106
safety of surgery for, 106
subdural electrode monitoring to define epileptogenic zone in,
103–104, 106
treatment in patients with multiple cavernous malformations,
106
treatment options for, 102–104
treatment recommendations for, 105, 105

Shackleton, Ernest, 5

Skull base tumor management, 35–37, 36, 36t–38t
acoustic neuroma, 35–36
gamma knife radiosurgery, 36–37, 36t–38t
new neurological deficits after microsurgery, 36
petroclival meningioma, 36, 36
radiation therapy, 37, 37t

Spinal cord injury (SCI), cannabinoid CB2 receptor activation in
(mouse), 172–176
bladder function improved by, 173, 174, 175, 176
CB2 agonist (O-1966) properties and injection, 173
locomotive function improved by, 173–174, 174
TNF-α expression decreased by, 172, 174–175, 175

Spinal fusion, enhancement of, 63–69
bioactive strategies, 65–66, 65t
bone marrow aspirate and blood spin-down technologies,
64, 66
bone morphogenetic proteins, 65–66
composite technologies, 66
cytokines and other inductive agents, 66
gene therapy, 66
biosensing strategies, 68–69, 70
complexity of bone loading, 68–69, 71
optimizing bone loading and bone-loading rates, 69
bone graft substitutes, 63–65
allograft, 63–64
components of bone healing, 64
demineralized bone matrix, 65
xenograft, 65
interbody spacers, 65, 65
phases of bone healing process, 63, 64
physical/mechanical strategies, 67–68, 68, 69
physiology enhancement and augmentation strategies, 66–67
direct current stimulation, 67
electrophysiological strategies, 66–67, 67
pulsed electromagnetic fields, 67
surgical technique, 63, 64
synthetic bone substitutes, 65, 66
today’s and tomorrow’s alternatives to autograft, 66
Spine Patient Outcomes Research Trial (SPORT), 72–75
of degenerative spondylolisthesis, 75
of herniated lumbar disc, 72–74, 73, 74t
Statute of limitations, 122
Stefansson, Vilhjalmur, 9, 9
Steiner, Ladislau, 108
Stem cells, 133–136
adult, 135–136
bone marrow or mesenchymal, 136
generation of, 133
neural, 133–135
development from embryonic stem cells, 133, 134
endogenous, 133
NT2 cell line, 133–134
role of neurotrophic and angiogenic factors in transplantation of, 134–135
transplantation in Parkinson’s disease, 133, 134, 135
umbilical cord blood cells in stroke, 136
Stereotactic procedures, 76–85
for brain abscess, 81
for brain cyst, 80, 80, 80t
craniotomy, 76, 80–81
development of dedicated stereotactic operating room, 76, 77, 84, 84–85
for endoscopic-assisted surgery, 82, 82, 83
frame-based, 77–79, 77–80, 77t
for biopsy, 78, 79
brain hemorrhage after, 79–80, 80t
complications of, 79–80, 79t–80t
frameless, 82–83
functional neurosurgery, 76, 81–82, 81t
radiosurgery (See Radiosurgery)
Stereotactic radiation therapy (SRT), for acoustic neuroma, 55–56
Stroke, umbilical cord blood cells in, 136
Surgical Planning System SPS, 84
SurgiScope, 83, 83–84
Synthetic bone substitutes, to enhance spinal fusion, 65, 66

and, 165–169, 166–169
case example of, 165–166, 166
clinical study results of, 167–169
evidence of hypermutator phenotype, 166, 166–167
prediction of, 167
Tf-CRM111, convection-enhanced delivery of, 30–31
Tinnitus, after acoustic neuroma removal, 48
Tort system, 121–125
alternatives to, 123–124
for birth-related injuries in Florida and Virginia, 124
“early offer” plan, 124
health courts, 124
in New Zealand, 123
patient indemnity insurance, 124
in Scandinavian countries, 123–124
description of, 121
“mainstream” tort reform measures, 122
Alternative Dispute Resolution, 122
collateral-source payments, 122
contingency fee, 122
effects of, 122–123
expert witness requirements, 122
healthcare costs and, 123
joint-and-several liability, 122
malpractice insurance premiums and, 122–123
noneconomic damage caps, 122
punitive damage caps, 122
statute of limitations, 122
problems with U.S. system, 121–122
TP-38, convection-enhanced delivery of, 30
Trigeminal nerve function, after acoustic neuroma radiosurgery, 55
Tumor necrosis factor-α (TNF-α) in spinal cord injury, decreased by CB2 agonist therapy (mouse), 172, 174–175, 175

U
Umbilical cord blood cells, in stroke, 136

V
Ventralateral radiosurgical hypothalamotomy, in obesity, 42–43, 42–43
Vestibular schwannoma. See Acoustic neuroma

X
Xenograft, to enhance spinal fusion, 65